VVT Med Touts Positive Vein Treatment Data from Indian Study

VANCOUVER, BC – April 30, 2026 – VVT Med Inc. (TSXV: VVTM), a medical device company focused on venous disease, today announced the publication of a clinical study showcasing positive results for its ScleroSafe® varicose vein treatment system. The data, published in the Indian Journal of Vascular and Endovascular Surgery, points to high safety and efficacy, bolstering the company's case for its minimally invasive technology. However, a deeper analysis of the study and the competitive landscape reveals a complex picture of a promising technology still needing to prove its long-term value in a crowded market.

A Closer Look at the Clinical Data

The study, titled "Efficacy and Safety of ScleroSafe Catheter-directed Sclerotherapy for Varicose Veins," was conducted at the Holy Spirit Hospital and Medical Research Centre in Mumbai, India. It followed 30 patients with symptomatic varicose veins who were treated between March and July 2025. The results, as highlighted by VVT Med, were impressive on the surface.

The procedure achieved a 100% technical success rate, meaning the catheter was successfully deployed in every patient. More importantly, the vein occlusion rate—a key measure of whether the treatment worked—was 95% after 30 days and remained high at 92% after 90 days. Patients also experienced significant and rapid symptom relief, with 80% reporting less leg heaviness, 65% less pain, and 40% less swelling within 24 hours of the office-based procedure. Critically, the study reported no serious adverse events such as deep vein thrombosis, nerve injury, or skin necrosis during the three-month follow-up period.

"The publication of this peer-reviewed study in an indexed, internationally recognized journal represents an important milestone for VVT Med," said Erez Tetro, Chief Executive Officer of VVT Med, in a press release. "Independent clinical data generated by vascular surgeons in routine practice... provides meaningful external support for the efficacy and safety profile we have observed across our global commercial deployments."

While the results are encouraging for the company, the study's context is crucial for a complete picture. The research was published in a journal with a relatively low impact factor and citation rate, suggesting it may have limited influence within the broader global scientific community. Furthermore, the study's design has several limitations inherent to early-stage clinical research. With only 30 patients from a single hospital and treated by a single surgeon, the results may not be generalizable to a wider population or reproducible by other practitioners. The 90-day follow-up period provides a good short-term snapshot but does not answer critical questions about long-term durability and the potential for vein recurrence, which are key considerations for both physicians and patients when evaluating treatment options.

The Shift Towards Non-Thermal Vein Treatment

The ScleroSafe system is part of a significant trend in medicine away from invasive surgery and towards minimally invasive, office-based procedures. Specifically, it falls into the category of non-thermal, non-tumescent (NT-NT) treatments. This distinguishes it from older methods like surgical vein stripping, which requires general anesthesia and significant recovery time, and more established minimally invasive techniques like thermal ablation.

Thermal ablation, which includes Endovenous Laser Ablation (EVLA) and Radiofrequency Ablation (RFA), uses heat to close the diseased vein. While highly effective, these methods require the injection of large volumes of tumescent anesthesia—a dilute anesthetic solution—along the length of the vein to numb the area and protect surrounding tissue from heat damage. This can be uncomfortable for the patient and adds time and complexity to the procedure.

NT-NT technologies aim to eliminate the need for both heat and tumescent anesthesia. VVT Med's ScleroSafe achieves this through a specialized dual-lumen catheter. It simultaneously injects a sclerosant—a chemical agent (polidocanol) that irritates and closes the vein—while aspirating blood from the site. This simultaneous action is designed to ensure the sclerosant has direct contact with the vein wall, improving efficacy while minimizing the amount of sclerosant that enters the bloodstream.

This approach places ScleroSafe in direct competition with other innovative NT-NT methods. Medtronic's VenaSeal™ system, for example, uses a medical-grade cyanoacrylate adhesive to glue the vein shut. Merz Aesthetics' ClariVein® system is a mechanochemical device that uses a rotating wire to damage the vein lining while simultaneously delivering a sclerosant. These technologies all promise a similar patient experience: a quick, office-based procedure with minimal pain, no need for general or tumescent anesthesia, and a rapid return to normal activities.

Global Ambitions and Market Realities

The decision to highlight a study from India is a strategic one for VVT Med. With ScleroSafe already holding FDA clearance in the United States and a CE Mark in Europe, demonstrating success in a large and growing international market like India supports the company's narrative of global adoption. It suggests the technology is not only effective but also adaptable to different healthcare systems and patient populations.

For a publicly traded company on the TSX Venture Exchange, such news is critical. Positive, peer-reviewed data provides tangible validation of the company's core technology, which can bolster investor confidence and potentially drive the stock's value. It helps de-risk the investment by showing that the product works as intended in a real-world clinical setting.

However, the path from positive short-term data to widespread commercial success is long. Physicians are often cautious adopters of new technology, weighing the potential benefits against the extensive long-term data available for established treatments like thermal ablation. To truly capture significant market share, VVT Med will need to continue building its evidence base with larger, randomized controlled trials that include longer-term follow-up and direct comparisons to its main competitors.

The company's financial success will ultimately depend on its ability to convince physicians and healthcare systems that ScleroSafe offers a compelling combination of clinical efficacy, patient satisfaction, and cost-effectiveness. The promise of avoiding the capital equipment costs associated with laser or radiofrequency generators is an attractive part of VVT Med's value proposition, particularly for smaller clinics or in healthcare systems with tight budget constraints. This recent study is an important step in building that case, but it is just one piece of a much larger and more complex puzzle.